The use of methadone for cancer pain

Gagnon, 1999, Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain, J Pain Symptom Manage, 18, 120, 10.1016/S0885-3924(99)00049-4

Gourlay, 1986, A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer, Pain, 25, 297, 10.1016/0304-3959(86)90234-4

Makin, 1998, Methadone in the management of cancer related neuropathic pain: report of five cases, Pain Clinic, 4, 275

Thomas, 1995, Use of methadone in a highly tolerant patient receiving parenteral hydromorphone, J Pain Symptom Manage, 10, 315, 10.1016/0885-3924(95)00011-M

Egbert, 1995, Ketobemidone, methadone and pethidine are non-competitive N-methyl-d-aspartate (NMDA) antagonists in the rat cortex and spinal cord, Neurosci Lett, 187, 165, 10.1016/0304-3940(95)11364-3

Gorman, 1997, The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-d -aspartate (NMDA) receptor in rat forebrain and spinal cord, Neurosci Lett, 223, 5, 10.1016/S0304-3940(97)13391-2

Price, 2000, NMDA-receptor antagonists and opioid receptor interactions as related to analgesia and tolerance, J Pain Symptom Manage, 19, S7, 10.1016/S0885-3924(99)00121-9

Portenoy, 2000, Current pharmacotherapy of chronic pain, J Pain Symptom Manage, 19, S16, 10.1016/S0885-3924(99)00124-4

Yaksh, 1997, Pharmacology and mechanisms of opioid analgesic activity, Acta Anaesthesiol Scand, 41, 94, 10.1111/j.1399-6576.1997.tb04623.x

Davis, 2001, Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration, Support Care Cancer, 9, 73, 10.1007/s005200000180

Jg, 1999, The difference between methadone and morphine in regulation of delta-opioid receptors underlies the antagonistic effect of methadone on morphine-mediated cellular actions, Eur J Pharmacol, 373, 233, 10.1016/S0014-2999(99)00270-8

Codd, 1995, Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception, J Pharmacol Exp Ther, 274, 1263

Bennett, 2000, Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-receptor, J Pain Symptom Manage, 19, S2, 10.1016/S0885-3924(99)00120-7

Jensen, 1997, Opioids in the brain: supraspinal mechanisms in pain control, Acta Anaesthesiol Scand, 41, 123, 10.1111/j.1399-6576.1997.tb04626.x

Inturrisi, 1972, Disposition of methadone in man after single oral dose, Pharmacol Ther, 13, 923, 10.1002/cpt1972136923

Nilsson, 1982, Clinical pharmacokinetics of methadone, Acta Anaesthesiol Scand, 74, 66, 10.1111/j.1399-6576.1982.tb01850.x

Abramson, 1982, Methadone plasma protein binding: alterations in cancer and displacement from alpha-1-acid glycoprotein, Clin Pharmacol Ther, 32, 652, 10.1038/clpt.1982.217

Eap, 1990, Binding of d-methadone, l-methadone and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of α1-acid glycoprotein, Clin Pharmacol Ther, 47, 338, 10.1038/clpt.1990.37

Plummer, 1988, Estimation of methadone clearance: application in the management of cancer pain, Pain, 33, 313, 10.1016/0304-3959(88)90290-4

Inturrisi, 1987, Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain, Clin Pharmacol Ther, 41, 392, 10.1038/clpt.1987.47

Lown, 1998, Sequences of intestinal and hepatic cytochrome P450 3A4 cDNA identical, Drug Metab Dispos, 26, 185

Bell ward, 1977, Methadone maintenance: effect of urinary pH on renal clearance in chronic high and low doses, Clin Pharmacol Ther, 22, 92, 10.1002/cpt197722192

Mercadante, 1997, Methadone in cancer pain, Eur J Pain, 1, 77, 10.1016/S1090-3801(97)90064-1

Bruera, 1995, Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain, Pain, 62, 141, 10.1016/0304-3959(94)00257-F

Ripamonti, 1997, An update on the clinical use of methadone for cancer pain, Pain, 70, 109, 10.1016/S0304-3959(96)03286-1

De Conno, 1996, Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients, J Clin Oncol, 14, 2836, 10.1200/JCO.1996.14.10.2836

Mercadante, 1999, Methadone response in advanced cancer patients with pain followed at home, J Pain Symptom Manage, 18, 188, 10.1016/S0885-3924(99)00048-2

Mercadante, 1996, Patient-controlled analgesia with oral methadone in cancer pain, Ann Oncol, 7, 613, 10.1093/oxfordjournals.annonc.a010679

Sawe, 1981, Patient-controlled dose regimen of methadone for chronic cancer pain, BMJ, 282, 771, 10.1136/bmj.282.6266.771

Mercadante, 1997, Treatment of pain in chronic bowel subobstruction with self-administration of methadone, Support Care Cancer, 5, 1, 10.1007/s005200050082

Ventafridda, 1986, A randomized study on oral administration of morphine and methadone in the treatment of cancer pain, J Pain Symptom Manage, 1, 203, 10.1016/S0885-3924(86)80042-2

Mercadante, 1998, Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home, J Clin Oncol, 16, 3656, 10.1200/JCO.1998.16.11.3656

Bruera, 1992, Custom-made suppositories of methadone for severe cancer pain, J Pain Symptom Manage, 7, 372, 10.1016/0885-3924(92)90093-W

Ripamonti, 1995, Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study, Ann Oncol, 6, 841, 10.1093/oxfordjournals.annonc.a059327

Bruera, 1991, Local toxicity with subcutaneous methadone. Experience of two centers, Pain, 45, 141, 10.1016/0304-3959(91)90179-2

Mathew, 1999, Subcutaneous methadone in terminally ill patients: manageable local toxicity, J Pain Symptom Manage, 18, 49, 10.1016/S0885-3924(99)00020-2

Weinberg, 1988, Sublingual absorption of selected opioid analgesics, Clin Pharmacol Ther, 44, 335, 10.1038/clpt.1988.159

Fitzgibbon, 1997, Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine, Pain, 73, 259, 10.1016/S0304-3959(97)00118-8

Manfredi, 1997, Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations, Pain, 70, 99, 10.1016/S0304-3959(96)03313-1

Shir, 1987, Prolonged continuous epidural methadone analgesic in the treatment of back and pelvic pain due to multiple myeloma, Pain Clin, 1, 255

Jacobson, 1990, Intrathecal methadone: a dose-response study and comparison with intrathecal morphine 0.5 mg, Pain, 41, 147

Bruera, 1996, Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine, Cancer, 78, 852, 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T

de Stoutz, 1995, Opioid rotation for toxicity reduction in terminal cancer patients, J Pain Symptom Manage, 10, 378, 10.1016/0885-3924(95)90924-C

Hunt, 1995, Respiratory depression in a patient receiving oral methadone for cancer pain, J Pain Symptom Manage, 10, 401, 10.1016/0885-3924(95)00021-P

Mercadante, 1999, Rapid switching from morphine to methadone in cancer patients with poor response to morphine, J Clin Oncol, 17, 1, 10.1200/JCO.1999.17.10.3307

Mercadante, 2001, Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study, J Clin Oncol, 19, 2898, 10.1200/JCO.2001.19.11.2898

Ripamonti, 1998, Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences, Ann Oncol, 9, 79, 10.1023/A:1008263910494

Vigano', 1996, Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators, Pain, 67, 115, 10.1016/0304-3959(96)03112-0

Bruera, 1990, Palliative care in a cancer center. Results in 1984 versus 1987, J Pain Symptom Manage, 5, 1, 10.1016/S0885-3924(05)80002-8

Cherny, 1995, Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration, Cancer, 76, 1283, 10.1002/1097-0142(19951001)76:7<1283::AID-CNCR2820760728>3.0.CO;2-0

Coyle, 1990, Character of terminal illness in the advanced cancer patients. Pain and other symptoms during the last four weeks of life, J Pain Symptom Manage, 5, 83, 10.1016/S0885-3924(05)80021-1

Anderson, 2001, Accuracy in equianalgesic dosing: conversion dilemmas, J Pain Symptom Manage, 21, 397, 10.1016/S0885-3924(01)00271-8

Bruera, 1995, Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation, J Pain Symptom Manage, 10, 287, 10.1016/0885-3924(95)00005-J

Cherny, 2001, Strategies to manage the adverse effects of oral morphine: an evidence-based report, J Clin Oncol, 19, 2542, 10.1200/JCO.2001.19.9.2542

Ripamonti, 2001, Strategies for the treatment of cancer pain in the new millennium, Drugs, 61, 955, 10.2165/00003495-200161070-00005

Hagen, 1999, Methadone: outpatient titration and monitoring strategies in cancer patients, J Pain Symptom Manage, 18, 369, 10.1016/S0885-3924(99)00083-4

Daeninck, 1999, Reduction in constipation and laxative requirements following opioid rotation to methadone: a report of four cases, J Pain Symptom Manage, 18, 303, 10.1016/S0885-3924(99)00086-X

Leng, 1994, Successful use of methadone in nociceptive cancer pain unresponsive to morphine, Palliat Med, 8, 153, 10.1177/026921639400800209

Mancini, 2000, Opioid switch to oral methadone in cancer pain, Curr Opin Oncol, 12, 308, 10.1097/00001622-200007000-00006

Morley, 1993, Methadone in pain uncontrolled by morphine, Lancet, 342, 1243, 10.1016/0140-6736(93)92228-L

Ripamonti, 1998, Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?, J Clin Oncol, 16, 3216, 10.1200/JCO.1998.16.10.3216

Mancini, 2000, Opioid type and other clinical predictors of laxative dose in advanced cancer patients: a retrospective study, Journal of Palliative Medicine, 3, 49, 10.1089/jpm.2000.3.49

Lawlor, 1998, Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study, Cancer, 82, 1167, 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.0.CO;2-3

Morley, 1998, The use of methadone in cancer pain poorly responsive to other opioids, Pain Rev, 5, 51, 10.1191/096813098673619329

Nauck F., Ostgathe C., Klaschik E., et al. A German model of methadone conversion [abstract 90]. In: Abstracts of the 13th MASCC/ISOO International Symposium. Copenhagen; 2001. p. 304.

Bernard, 2000, Drug interactions in palliative care, J Clin Oncol, 18, 1780, 10.1200/JCO.2000.18.8.1780

Mercadante, 1999, Methadone response in advanced cancer patients with pain followed at home, J Pain Symptom Manage, 18, 188, 10.1016/S0885-3924(99)00048-2

Wu, 1993, Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone, Br J Clin Pharmacol, 35, 30, 10.1111/j.1365-2125.1993.tb05666.x

Denton, 1949, New analgesics, JAMA, 141, 1146, 10.1001/jama.1949.62910160003009

Faisinger, 1993, Methadone in the management of cancer pain: a review, Pain, 52, 137, 10.1016/0304-3959(93)90125-9

Santiago-Palma, 2001, Intravenous methadone in the management of chronic cancer pain. Safe and effective starting doses when substituting methadone for fentanyl, Cancer, 92, 1919, 10.1002/1097-0142(20011001)92:7<1919::AID-CNCR1710>3.0.CO;2-G